« Amgen: Brace Yourselves |
| The Singularity, Postponed »
October 17, 2011
Harvard to the Rescue
Harvard is announcing a big initiative in systems biology, which is an interdisciplinary opportunity if there ever was one.
The Initiative in Systems Pharmacology is a signature component of the HMS Program in Translational Science and Therapeutics. There are two broad goals: first, to increase significantly our knowledge of human disease mechanisms, the nature of heterogeneity of disease expression in different individuals, and how therapeutics act in the human system; and second — based on this knowledge — to provide more effective translation of ideas to our patients, by improving the quality of drug candidates as they enter the clinical testing and regulatory approval process, thereby aiming to increase the number of efficacious diagnostics and therapies reaching patients.
All worthy stuff, of course. But there are a few questions that come up. These drug candidates that Harvard is going to be improving the quality of. . .whose are those, exactly? Harvard doesn't develop drugs, you know, although you might not realize that if you just read the press releases. And the e-mail announcement sent out to the Harvard Medical School list is rather less modest about the whole effort:
With this Initiative in Systems Pharmacology, Harvard Medical School is reframing classical pharmacology and marshaling its unparalleled intellectual resources to take a novel approach to an urgent problem: The alarming slowdown in development of new and lifesaving drugs.
A better understanding of the whole system of biological molecules that controls medically important biological behavior, and the effects of drugs on that system, will help to identify the best drug targets and biomarkers. This will help to select earlier the most promising drug candidates, ultimately making drug discovery and development faster, cheaper and more effective. A deeper understanding will also help clinicians personalize drug therapies, making better use of medicine we already have.
Again with all those drug candidates - and again, whose candidates are they going to be selecting? Don't get me wrong; I actually wish everyone well in this effort. There really are a lot of excellent scientists at Harvard, even if they tell you so, and this is the sort of problem that can take (and has taken) everything that people can throw at it. But it's also worth remembering Harvard's approach to licensing and industrial collaboration. It's. . .well, let's just say that they didn't get that endowment up to its present size by letting much slip through their fingers. Many are those who've negotiated with the university and come away wanting to add ". . .et Pecunia" to that Latin motto.
So we'll see what comes out of this. But Harvard Medical School is indeed on the case.
+ TrackBacks (0) | Category: Drug Development
POST A COMMENT
- RELATED ENTRIES
- The Last Post
- The GSK Layoffs Continue, By Proxy
- The Move is Nigh
- Another Alzheimer's IPO
- Cutbacks at C&E News
- Sanofi Pays to Get Back Into Oncology
- An Irresponsible Statement About Curing Cancer
- Oliver Sacks on Turning Back to Chemistry